![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
X
20
Fujisawa Pharmaceutical Co Ltd Osaka Jp, based in Japan, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their significant offerings is Ceftizoxime sodium, supported by a 'Expired' Certificate of Suitability (CEP) with the number R0-CEP 2001-072 - Rev 02
This TSE Type CEP, issued on February 28, 2005, remains in force until May 03, 2007, ensuring its reliability within the pharmaceutical industry.